CHCarsten Hafer

Carsten Hafer

*This is an algorithmically generated author record based on publicly available information.

Carsten Hafer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SaO040TREATMENT OF BACTEREMIA DURING DIALYSIS USING A BIOMIMETIC SORBENT HEMOPERFUSION DEVICE - RESULTS OF AN ONGOING FIRST-IN-HUMAN STUDY

    by Gabriele Eden, Philipp Kümpers, Robert Ward, Keith McCrea, Kathy White, Carsten Hafer, Jan T Kielstein

    INTRODUCTION AND AIMS: Fast reduction of bacterial burden has been shown to be crucial in improving survival of patients with bacteremia, resulting in a quest for treatment strategies that can be used in addition to the timely administration of antibiotics. One strategy hijacks a defense mechanisms of many pathogens to subvert the host immune response, i.e. the binding to heparan sulfate, a key receptor on cell surfaces. In preclinical testing a device, consisting of a column packed with beads grafted with biologically active heparin did bind many drug-resistant and drug-susceptible bacteria, thereby quickly reducing bacterial load in the blood. In addition this device, the Seraph® 100 Blood Filter (Seraph), also removes toxins, and cytokines. Aim of this first in human study was to asses safety and collect initial data on performance of the Serph in hemodialysis patients with bacteremia.


  • Opponent's comments.

    by Carsten Hafer, Jan T. Kielstein


  • Akute Nierenschädigung

    by Carsten Hafer, Jan T. Kielstein

    Bereits leichtgradige Nierenfunktionseinbußen gehen mit einer erhöhten Morbidität und Mortalität einher. Frühzeitig sollte man eine nephrologische Konsultation anberaumen. Urinmikroskopie und Sonografie sind wesentlich Elemente der nephrologischen Diagnostik. Biomarker haben derzeit allenfalls einen begrenzten klinischen Nutzen. Frühzeitige hämodynamische Optimierung mit chloridarmen, bilanzierten Vollelektrolytlösungen Bei unzureichender Besserung und Anurie ist eine restriktive Volumentherapie vorteilhaft. Katecholamin der Wahl ist nach derzeitigem Kenntnisstand Noradrenalin. Überwachung der verordneten Nierenersatztherapie und der potenziellen Komplikationen.


  • Open Access

    Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients

    by Johannes Hadem, Carsten Hafer, Andrea S Schneider, Olaf Wiesner, Gernot Beutel, Thomas Fuehner, Tobias Welte, Marius M Hoeper, Jan T Kielstein

    Several case series and small randomized controlled trials suggest that therapeutic plasma exchange (TPE) improves coagulation, hemodynamics and possibly survival in severe sepsis. However, the exact role of TPE in modern sepsis therapy remains unclear.


  • Open Access

    Effect of acute kidney injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing interventional lung assist membrane ventilator treatment

    by Jan T Kielstein, Soeren Tolk, Carsten Hafer, Anna Heiden, Olaf Wiesner, Christian Kühn, Johannes Hadem, Marius M Hoeper, Stefan Fischer

    Extracorporeal lung assist devices are increasingly used in the intensive care unit setting to improve extracorporeal gas exchange mainly in patients with acute respiratory distress syndrome. ARDS is frequently accompanied by acute kidney injury; however it is so far unknown how the combination of these two conditions affects long term survival of critically ill patients.


  • Akutes Nierenversagen

    by C. Hafer, J.T. Kielstein


  • Open Access

    Biopsy proven acute interstitial nephritis after treatment with moxifloxacin

    by Christos Chatzikyrkou, Iyas Hamwi, Christian Clajus, Jan Becker, Carsten Hafer, Jan T Kielstein

    Acute interstitial nephritis (AIN) is an important cause of reversible acute kidney injury. At least 70% of AIN is caused by various drugs, mainly penicillines and non-steroidal anti-inflammatory drugs. Quinolones are only rarely known to cause AIN and so far cases have been mainly described with older fluoroquinolones.


  • Open Access

    Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury

    by Philipp Kümpers, Carsten Hafer, Alexander Lukasz, Ralf Lichtinghagen, Korbinian Brand, Danilo Fliser, Robert Faulhaber-Walter, Jan T Kielstein

    Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is a promising novel biomarker that correlates with the severity and outcome of acute kidney injury (AKI). However, its prognostic utility during the late course of AKI, especially in patients that require renal replacement therapy (RRT) remains unknown. The aim of this study was to evaluate the predictive value of serum NGAL in patients with established AKI at inception of RRT in the intensive care unit (ICU). Methods: Serum NGAL (ELISA methodology) was measured in 109 critically ill patients with AKI at inception of RRT in 7 ICUs of a tertiary care university hospital. The primary outcome studied was 28-day mortality. Secondary outcome measures were ICU length of stay, ventilator-free days, and renal recovery at day 28. Results: There was a significant difference in serum NGAL between healthy subjects (median [interquartile range] 39.0 [37.5-42.75] ng/mL), critically ill patients with systemic inflammatory response syndrome (SIRS) (297 [184-490] ng/mL), and critically ill patients with sepsis (708 [365-1301] ng/mL; P < 0.0001), respectively. Multiple linear regression showed that NGAL levels were independently related to the severity of AKI and the extent of systemic inflammation. NGAL levels were higher in non-survivors (430 [303-942] ng/mL) compared to survivors (298 [159-506] ng/mL; P = 0.004). Consistently, Cox proportional hazards regression analysis identified NGAL as a strong independent predictor for 28-day survival (hazard ratio 1.6 (95% confidence interval [CI] 1.15 - 2.23), P = 0.005). Conclusions: This is the first prospective evaluation of serum NGAL as an outcome-specific biomarker in critically ill patients at initiation of RRT. The results from this study indicate that serum NGAL is as an independent predictor of 28-day mortality in ICU patients with dialysis-dependent AKI.


  • Open Access

    Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients

    by Philipp Kümpers, Alexander Lukasz, Sascha David, Rüdiger Horn, Carsten Hafer, Robert Faulhaber-Walter, Danilo Fliser, Hermann Haller, Jan T Kielstein

    Introduction: The endothelial specific angiopoietin (Ang)-Tie2 ligand-receptor system has been identified as a non-redundant mediator of endothelial activation in experimental sepsis. Binding of circulating Ang-1 to the Tie2 receptor protects the vasculature from inflammation and leakage, whereas binding of Ang-2 antagonises Tie2 signalling and disrupts endothelial barrier function. Here, we examine whether circulating Ang-1 and/or Ang-2 independently predict mortality in a cohort of critically ill medical patients. Methods: Circulating vascular endothelial growth factor (VEGF), Ang-1 and Ang-2 were prospectively measured in sera from 29 healthy controls and 43 medical ICU patients by immunoradiometric assay (IRMA) and ELISA, respectively. Survival after 30 days was the primary outcome studied. Results: Median serum Ang-2 concentrations were increasingly higher across the following groups: healthy controls, patients without sepsis, patients with sepsis and patients with septic shock. In contrast, Ang-1 and VEGF concentrations were significantly lower in all patient groups compared with healthy controls. Ang-2 correlated with partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FiO2), tissue hypoxia, Sequential Organ Failure Assessment (SOFA) and Physiology and Chronic Health Evaluation II (APACHE II) score. Multivariate Cox regression analyses confirmed a strong independent prognostic impact of high Ang-2 as a novel marker of 30-day survival. Conclusions: A marked imbalance of the Ang-Tie system in favour of Ang-2 is present in critically ill medical patients. Our findings highlight the independent prognostic impact of circulating Ang-2 in critical illness. Ang-2 may be used as a readily available powerful predictor of outcome and may open new perspectives to individualise treatment in the ICU.